Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Brielle Benyon
The Food and Drug Administration (FDA) approved a split-dosing regimen for Darzalex (daratumumab) for the treatment of patients with multiple myeloma.
Cora Fahy
A mastectomy can leave a lasting mark. This breast cancer survivor found her own unique way to make it a beautiful one.
Kristie L. Kahl
CURE® spoke with CEO Linda Tantawi about addressing the needs of underserved communities and how education is key in helping women in the Greater New York City area.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to Bavencio (avelumab) in combination with Inlyta (axitinib) to treat patients with advanced renal cell carcinoma (RCC).
Kristie L. Kahl
Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to phase 3 findings published in the New England Journal of Medicine.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Brielle Benyon
A preclinical study showed that FGL2 protein suppression may stop tumor cell growth in patients with glioblastoma.
Kristie L. Kahl
Check out this week’s quick overview of what is making headlines in the cancer space.
Beth Fand Incollingo
The Cholangiocarcinoma Foundation has won a grant from Bayer to create a website and outreach to patients and doctors to let them know that all patients with the disease need to have their tumors sequenced, because there are existing medicines/clinical trials that may help patients with actionable mutations more than the standard of care.
Alexandra Guadagno
Obesity may be to blame for increasing rates of certain cancers in young adults.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other